ICRA assigns Jubilant Pharmova at AA, outlook Stable
Jubilant Pharmova (JUBLPHARMA) said ICRA has assigned its credit rating at AA with a stable outlook. The company is valued at about ₹15,146 crore.
What happened
Jubilant Pharmova (JUBLPHARMA) told the exchanges on 14 October 2026 at 04:31 PM that ICRA has assigned its credit rating at AA with a stable outlook.
From the filing: "Date and time of receipt of the rating communication : October 13, 2026, at 5:09 p.m. (IST )."
Company snapshot
Jubilant Pharmova is a small-cap company in the Healthcare sector, with a market value of about ₹15,146 crore.
The stock last traded at ₹950.9, against a 52-week range of ₹786.1–₹1,184.8 (19.7% below the high).
Before this filing the shares had moved −7.3% over the month and −2.4% over three months. Average daily turnover over the last 20 sessions was about ₹30.19 crore.
Promoters held 47.68% at the end of Q1 FY27; 6.58% of promoter shares were pledged. Foreign institutions owned 15.87% and domestic institutions 12.40%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,901 | 102.9 | 6.49 |
| Q2 FY26 | 1,966 | 120.3 | 7.59 |
| Q3 FY26 | 2,123 | 55.9 | 3.52 |
| Q4 FY26 | 2,290 | 119.4 | 7.55 |
| Q1 FY27 | 2,229 | 56.5 | 3.57 |
What history shows
BCEIE has no earlier credit rating filing from this company on record since May 2026.
Across 28 similar disclosures by other Healthcare companies, shares moved +0.0% on average the next day and +1.6% over five days; 61% of them rose the next day.
Market-wide, 1,275 credit rating filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 46% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Whether other agencies take a similar view on the company's credit.
In the news
Recent coverage elsewhere (links open the original publisher):
- Quant MF sells Jubilant Pharmova stake for over ₹100 crore; stock falls over 2%
- Jubilant Pharmova Board Approves ₹800 Crore NCD Issue And Seeks ₹2,500 Crore Debt Approval
- Jubilant Pharmova radiopharma unit to invest CAD 94.5 million to double RUBY-FILL production
- Jubilant Pharmova radiopharma unit to invest CAD 94.5 million to double RUBY-FILL production - CNBC TV18
- Jubilant Pharmova to Raise ₹800 Cr Via NCD Issue
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.